An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 216606
Company: AMTA

Products on ANDA 216606

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
NISOLDIPINE	NISOLDIPINE	8.5MG	TABLET, EXTENDED RELEASE;ORAL	Discontinued	None	No	No
NISOLDIPINE	NISOLDIPINE	17MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB	No	No

Approval Date(s) and History, Letters, Labels, Reviews for ANDA 216606

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
04/10/2023	ORIG-1	Approval		STANDARD		Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
12/12/2025	SUPPL-2	Labeling-Container/Carton Labels		Label is not available on this site.

Therapeutic Equivalents for ANDA 216606

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL; 17MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
NISOLDIPINE	NISOLDIPINE	17MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	216606	AMTA
NISOLDIPINE	NISOLDIPINE	17MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	No	AB	091001	MYLAN
SULAR	NISOLDIPINE	17MG	TABLET, EXTENDED RELEASE;ORAL	Prescription	Yes	AB	020356	AZURITY

Top